Efficacy and Safety of Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome

NCT06697119 | Active Not Recruiting DMC

• 1 other identifier: B-2210-784-004
• Study Type: interventional
• Target: 44
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to assess the efficacy and safety of fecal microbiota transplantation (FMT) for patients with irritable bowel syndrome (IBS). The main objectives of the study are: To determine if FMT can significantly reduce IBS symptoms and improve patients' quality of life. To evaluate any potential adverse effects associated with FMT in IBS patients. Researchers will compare outcomes in patients receiving FMT with a standard care protocol to gauge the effectiveness of FMT in alleviating IBS symptoms. Participants will: Receive FMT via endoscopic methods as per the study protocol. Attend scheduled clinic visits for assessments and symptom tracking over a 48-week period, with optional long-term follow-up for up to 3 years. Complete regular questionnaires and microbiota assessments to monitor symptoms and gut health changes over time.

Conditions

Irritable Bowel Disease

Keywords

fecal microbiota transplantation; FMT; IBS; Irritable bowel disease

Outcome Measures

Primary Outcomes (1)

• Changes of IBS-SSS

  At 12 weeks post-FMT, overall satisfaction with the improvement in IBS symptoms will be evaluated, alongside changes in the IBS Symptom Severity Score (IBS-SSS) to comprehensively assess the effects of FMT on individual IBS symptoms.

  12weeks after FMT

Secondary Outcomes (5)

• Change in IBS-SSS

  4 weeks, 24 weeks, 48 weeks, 2 years, and 3 years after FMT

• Changes in Stool Frequency and Form

  4 weeks, 12 weeks, 24 weeks, 48 weeks, 2 years, and 3 years after FMT

• Changes in Quality of Life

  4 weeks, 12 weeks, 24 weeks, 48 weeks, 2 years, and 3 years after FMT

• Changes in Anxiety and Derpession

  4 weeks, 12 weeks, 24 weeks, 48 weeks, 2 years, and 3 years after FMT

• Changes in gut microbiota

  at baseline, 4 weeks, and 12 weeks after FMT

Study Arms (1)

FMT

EXPERIMENTAL

Fecal microbiota transplantation: fecal suspension delivered to duodenal 3rd portion via esophagogastroduodenoscopy

Other: Fecal Microbial Transplantation

Interventions

Fecal Microbial Transplantation OTHER

Fecal suspension is delivered to duodenal 3rd portion via esophagogastroduodenoscopy

FMT

Eligibility Criteria

• Age: 19 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Korean men and women aged 19 to 80 years
• Diagnosed according to Rome IV criteria, with abdominal pain occurring at least once per week that began more than 6 months prior and has recurred over the past 3 months, accompanied by at least two of the following symptoms: pain related to defecation, changes in stool frequency (increase or decrease), or changes in stool form (looser or harder consistency)
• Patients with moderate to severe IBS (IBS-SSS score of 175 or higher) with diarrhea-predominant, mixed-type, or abdominal bloating as the main symptom, who have not responded to IBS medication therapy for over 3 months
• Patients who have had a colonoscopy within the past 5 years, or those who will undergo a colonoscopy after joining the study, and for whom no structural abnormalities in the colon are identified (records from other hospitals within the past 5 years may be used). \*Patients who have undergone a biopsy or polypectomy during colonoscopy and can provide examination results are eligible if deemed appropriate by the clinician
• Females who are surgically infertile or females of childbearing potential with a negative pregnancy test (urine hCG or serum b-hCG); females of childbearing potential or males who agree to use effective contraception (e.g., oral contraceptives, IUD, double-barrier methods, or hormonal implants) during the study period
• Individuals capable of clearly expressing their intentions without significant neurological or psychiatric issues. Those with neurological or psychiatric conditions may participate if deemed stable with appropriate medication or other treatments
• Patients who voluntarily provide written informed consent to participate in the study

You may not qualify if:

• Pregnant or breastfeeding women
• Patients who have received investigational drugs within 3 months prior to Visit 1 (if investigational drugs were used within 3 months, consult the study monitor for case-by-case assessment)
• Patients whom the investigator deems to be at risk or to have conditions that would interfere with participation in the clinical trial
• Patients with severe congestive heart failure or severe angina
• Patients diagnosed with lactose intolerance or those who are immunocompromised
• Patients currently taking medications that may affect the study drug (e.g., intestinal drugs, probiotics), or those who need to continue these medications during the study period. Patients who are currently on these medications can participate after a 2-week washout period
• Patients whose systolic blood pressure exceeds 160 mmHg or diastolic blood pressure exceeds 100 mmHg at Visit 1, with uncontrolled hypertension regardless of treatment status
• Patients with uncontrolled endocrine disorders (e.g., diabetes), metabolic disorders (e.g., secondary hyperlipidemia), or hypothyroidism. Patients with a history of hypothyroidism may participate if they have been on a stable thyroid hormone replacement therapy for at least 4 weeks before Visit 2 and have a TSH level within the normal range at Visit 2
• Patients with impaired renal function (creatinine \> 2.0 mg/dL) or nephrotic syndrome at Visit 1
• Patients with a history of cancer within the last 5 years (except for those deemed cured)
• Patients with significant psychiatric instability or psychiatric disorders not adequately controlled with medication or other treatment
• Patients who have taken systemic steroid medications within 1 month prior to Visit 1
• Patients who have undergone abdominal surgery other than appendectomy, cholecystectomy, cesarean section, hernia repair, or hysterectomy. \*Patients with other abdominal surgeries may still participate if deemed eligible by the investigator
• Any other patient whom the investigator deems unsuitable for the study

Sponsors & Collaborators

• Seoul National University Hospital: lead

Study Sites (1)

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, South Korea

Location

Related Publications (5)

• Wu J, Lv L, Wang C. Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials. Front Cell Infect Microbiol. 2022 Feb 28;12:827395. doi: 10.3389/fcimb.2022.827395. eCollection 2022.

  PMID: 35295757 BACKGROUND

• El-Salhy M, Hatlebakk JG, Gilja OH, Brathen Kristoffersen A, Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020 May;69(5):859-867. doi: 10.1136/gutjnl-2019-319630. Epub 2019 Dec 18.

  PMID: 31852769 BACKGROUND

• Aroniadis OC, Brandt LJ, Oneto C, Feuerstadt P, Sherman A, Wolkoff AW, Kassam Z, Sadovsky RG, Elliott RJ, Budree S, Kim M, Keller MJ. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2019 Sep;4(9):675-685. doi: 10.1016/S2468-1253(19)30198-0. Epub 2019 Jul 17.

  PMID: 31326345 BACKGROUND

• Halkjaer SI, Christensen AH, Lo BZS, Browne PD, Gunther S, Hansen LH, Petersen AM. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018 Dec;67(12):2107-2115. doi: 10.1136/gutjnl-2018-316434. Epub 2018 Jul 6.

  PMID: 29980607 BACKGROUND

• Holvoet T, Joossens M, Vazquez-Castellanos JF, Christiaens E, Heyerick L, Boelens J, Verhasselt B, van Vlierberghe H, De Vos M, Raes J, De Looze D. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial. Gastroenterology. 2021 Jan;160(1):145-157.e8. doi: 10.1053/j.gastro.2020.07.013. Epub 2020 Jul 15.

  PMID: 32681922 BACKGROUND

MeSH Terms

Conditions

Irritable Bowel Syndrome

Condition Hierarchy (Ancestors)

Colonic Diseases, Functional; Colonic Diseases; Intestinal Diseases; Gastrointestinal Diseases; Digestive System Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 17, 2024
• First Posted: November 20, 2024
• Study Start: March 9, 2023
• Primary Completion: July 3, 2024
• Study Completion (Estimated): April 25, 2027
• Last Updated: November 20, 2024

Record last verified: 2024-11

Locations

KR (1)